On consolidated basis
Quarter ended June 2026 compared with Quarter ended June 2025.
Net sales (including other operating income) of Ipca Laboratories has increased 20.76% to Rs 2788.1 crore. Sales of India segment has gone up 13.48% to Rs 1,229.21 crore (accounting for 44.09% of total sales). Sales of Outside India segment has gone up 27.19% to Rs 1,558.89 crore (accounting for 55.91% of total sales). Operating profit margin has jumped from 18.04% to 24.01%, leading to 60.78% rise in operating profit to Rs 669.51 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 26.14% to 23.04%. Purchase of finished goods cost fell from 5.37% to 5.08%. Employee cost decreased from 23.00% to 21.72%. Other expenses fell from 27.86% to 25.99%. Other income fell 22.66% to Rs 25.26 crore. PBIDT rose 54.71% to Rs 694.77 crore. Provision for interest fell 35.82% to Rs 11.88 crore. PBDT rose 58.60% to Rs 682.89 crore. Provision for depreciation rose 10.74% to Rs 110.81 crore. Profit before tax grew 73.09% to Rs 572.08 crore. Provision for tax was expense of Rs 149.27 crore, compared to Rs 96.09 crore. Effective tax rate was 26.03% compared to 29.21%. Net profit attributable to owners of the company increased 72.33% to Rs 401.89 crore. Promoters’ stake was 44.72% as of 30 June 2026 ,compared to 44.72% as of 30 June 2025 .
Full year results analysis.
Net sales (including other operating income) of Ipca Laboratories has increased 7.91% to Rs 9646.33 crore. Sales of India segment has gone up 8.53% to Rs 4,386.62 crore (accounting for 45.47% of total sales). Sales of Outside India segment has gone up 7.39% to Rs 5,259.71 crore (accounting for 54.53% of total sales). Operating profit margin has jumped from 19.31% to 20.51%, leading to 14.62% rise in operating profit to Rs 1,978.56 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 25.34% to 24.16%. Purchase of finished goods cost fell from 6.10% to 5.49%. Employee cost increased from 22.08% to 22.27%. Other expenses rose from 27.28% to 27.68%. Other income rose 87.98% to Rs 174.45 crore. PBIDT rose 18.37% to Rs 2153.01 crore. Provision for interest fell 10.59% to Rs 75.94 crore. Loan funds declined from Rs 1,362.74 crore as of 31 March 2025 to Rs 808.76 crore as of 31 March 2026. Inventories rose to Rs 2,731.00 crore as of 31 March 2026 from Rs 2,560.42 crore as of 31 March 2025. Sundry debtors were higher at Rs 2,014.26 crore as of 31 March 2026 compared to Rs 1,873.82 crore as of 31 March 2025. Cash and bank balance rose to Rs 564.59 crore as of 31 March 2026 from Rs 344.23 crore as of 31 March 2025. Investments declined from Rs 979.71 crore as of 31 March 2025 to Rs 843.56 crore as of 31 March 2026. PBDT rose 19.78% to Rs 2077.07 crore. Provision for depreciation rose 5.10% to Rs 418.12 crore. Fixed assets increased to Rs 5,202.40 crore as of 31 March 2026 from Rs 4,798.00 crore as of 31 March 2025. Intangible assets increased from Rs 90.58 crore to Rs 197.58 crore. Profit before tax grew 24.16% to Rs 1,658.95 crore. Share of profit/loss was 231.44% lower at Rs -7.59 crore. Extraordinary items were increased to Rs -86.43 crore. Provision for tax was expense of Rs 381.15 crore, compared to Rs 343.61 crore. Effective tax rate was 24.36% compared to 30.44%. Minority interest decreased 10.30% to Rs 42.66 crore. Net profit attributable to owners of the company increased 54.69% to Rs 1,141.12 crore. Equity capital stood at Rs 25.37 crore as of 31 March 2026 to Rs 25.37 crore as of 31 March 2025. Per share face Value remained same at Rs 1.00. Promoters’ stake was 44.72% as of 31 March 2026 ,compared to 44.72% as of 31 March 2025 . Cash flow from operating activities decreased to Rs 1,141.97 crore for year ended March 2026 from Rs 1,321.32 crore for year ended March 2025. Cash flow used in acquiring fixed assets during the year ended March 2026 stood at Rs 655.91 crore, compared to Rs 775.52 crore during the year ended March 2025. Other Highlights
In Q1 FY27, formulations revenue grew 19% YoY, while API grew 30% YoY.
In Q1 FY27, exports grew 34% YoY.
| Ipca Laboratories : Consolidated Results | | | Quarter ended | Year ended |
|---|
| Particulars | 202606 | 202506 | Var.(%) | 202603 | 202503 | Var.(%) |
|---|
| Net Sales (including other operating income) | 2,788.10 | 2,308.85 | 20.76 | 9,646.33 | 8,939.59 | 7.91 | | OPM (%) | 24.01 | 18.04 | 598 bps | 20.51 | 19.31 | 120 bps | | OP | 669.51 | 416.42 | 60.78 | 1,978.56 | 1,726.14 | 14.62 | | Other Inc. | 25.26 | 32.66 | -22.66 | 174.45 | 92.80 | 87.98 | | PBIDT | 694.77 | 449.08 | 54.71 | 2,153.01 | 1,818.94 | 18.37 | | Interest | 11.88 | 18.51 | -35.82 | 75.94 | 84.93 | -10.59 | | PBDT | 682.89 | 430.57 | 58.60 | 2,077.07 | 1,734.01 | 19.78 | | Depreciation | 110.81 | 100.06 | 10.74 | 418.12 | 397.82 | 5.10 | | PBT | 572.08 | 330.51 | 73.09 | 1658.95 | 1336.19 | 24.16 | | Share of Profit/(Loss) from Associates | 1.46 | -1.53 | LP | -7.59 | -2.29 | -231.44 | | PBT before EO | 573.54 | 328.98 | 74.34 | 1651.36 | 1333.9 | 23.80 | | EO Income | 0 | 0 | - | -86.43 | -205.05 | 57.85 | | PBT after EO | 573.54 | 328.98 | 74.34 | 1564.93 | 1128.85 | 38.63 | | Taxation | 149.27 | 96.09 | 55.34 | 381.15 | 343.61 | 10.93 | | PAT | 424.27 | 232.89 | 82.18 | 1183.78 | 785.24 | 50.75 | | Minority Interest (MI) | 22.38 | -0.32 | PL | 42.66 | 47.56 | -10.30 | | Net profit | 401.89 | 233.21 | 72.33 | 1141.12 | 737.68 | 54.69 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 401.89 | 233.21 | 72.33 | 1141.12 | 737.68 | 54.69 | | EPS (Rs)* | 15.84 | 9.19 | 72.33 | 47.47 | 34.36 | 38.13 | | | * EPS is on current equity of Rs 25.37 crore, Face value of Rs 1, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
| Ipca Laboratories : Consolidated Segment Results | | | Quarter ended | Year ended |
|---|
| % of (Total) | 202606 | 202506 | Var.(%) | % of (Total) | 202603 | 202503 | Var.(%) |
|---|
| Sales | | India | 44.09 | 1,229.21 | 1,083.17 | 13.48 | 45.47 | 4,386.62 | 4,042.02 | 8.53 | | Outside India | 55.91 | 1,558.89 | 1,225.68 | 27.19 | 54.53 | 5,259.71 | 4,897.57 | 7.39 | | Total Reported Sales | 100.00 | 2,788.10 | 2,308.85 | 20.76 | 100.00 | 9,646.33 | 8,939.59 | 7.91 | | Less: Inter segment revenues | | 0.00 | 0.00 | - | | 0.00 | 0.00 | - | | Net Sales | 100.00 | 2,788.10 | 2,308.85 | 20.76 | 100.00 | 9,646.33 | 8,939.59 | 7.91 | | PBIT | | India | 0.00 | 0.00 | 0.00 | - | | Outside India | 0.00 | 0.00 | 0.00 | - | | Total PBIT | 100.00 | 0.00 | 0.00 | - | 100.00 | 0.00 | 0.00 | - | | Less : Interest | | 0.00 | 0.00 | - | | 0.00 | 0.00 | - | | Add: Other un-allcoable | | 0.00 | 0.00 | - | | 0.00 | 0.00 | - | | PBIT Margin(%) | | India | | 0.00 | 0.00 | 0.00 | | Outside India | | 0.00 | 0.00 | 0.00 | | PBT | 100.00 | 0.00 | 0.00 | - | 100.00 | 0.00 | 0.00 | - |
|
|